Naxitamab Combination Therapy for Patients With Neuroblastoma By: Madaline Spencer| Published on: Sep 3, 2025 +++++ +++++...

https://checkrare.com/naxitamab-combination-therapy-for-patients-with-neuroblastoma/ CLINICAL PERSPECTIVES Education Campaign for Thyroid Eye Disease https://checkrare.com/education-campaign-for-thyroid-eye-disease/ Margarita Ochoa-Maya, MD, Medical Director of the Rare Disease Business Unit at Amgen, discusses the TEDucation campaign for thyroid eye disease (TED). Naxitamab Combination Therapy for Patients With Neuroblastoma https://checkrare.com/naxitamab-combination-therapy-for-patients-with-neuroblastoma/ Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses naxitamab combination therapy for the treatment of patients with relapsed/refractory high-risk neuroblastoma. Diagnosing and Treating a Patient With Castleman Disease https://checkrare.com/diagnosing-and-treating-a-patient-with-castleman-disease/ Robin Williams, MD, Pediatric Hematology Oncologist at M Health Fairview Masonic Children’s Hospital, discusses her experience diagnosing and treating a patient with Castleman disease (CD). Mental Health in Patients With Acromegaly https://checkrare.com/mental-health-in-patients-with-acromegaly/ Lori Bulpett, Manager of Patient Advocacy at Chiesi Global Rare Diseases, discusses mental health in patients with acromegaly. SMAshing My Limits https://checkrare.com/smashing-my-limits/ Tracey Dawson, PhD, SVP, U.S. Therapeutic Area Head of Neuroscience at Novartis, discusses the SMAshing My Limits campaign for spinal muscular atrophy. Recordati’s Presentations at ENDO 2025 https://checkrare.com/recordatis-presentations-at-endo-2025/ Mario Maldonado, MD, Global Head of Clinical Development for Endocrinology at Recordati Rare Diseases, discusses Recordati’s presentations at ENDO 2025. Atumelnant for the Treatment of Congenital Adrenal Hyperplasia https://checkrare.com/atumelnant-for-the-treatment-of-congenital-adrenal-hyperplasia/ Alan Krasner, MD, Chief Endocrinologist at Crinetics Pharmaceuticals, discusses atumelnant for the treatment of patients with congenital adrenal hyperplasia (CAH). Disparities Between Biochemical Control and Symptom Burden in Patients With Acromegaly https://checkrare.com/disparities-between-biochemical-control-and-symptom-burden-in-patients-with-acromegaly/ Jason Crompton, PharmD, Global Medical Director of the Acromegaly Program at Chiesi Rare Diseases, discusses disparities between biochemical control and symptom burden in patients with acromegaly. Recordati Rare Disease Initiatives https://checkrare.com/recordati-rare-disease-initiatives/ Mohamed Ladha, President and General Manager for Recordati Rare Diseases North America, discusses the company’s rare disease initiatives. Data on Paltusotine for the Treatment of Acromegaly https://checkrare.com/data-on-paltusotine-for-the-treatment-of-acromegaly/ Alan Krasner, MD, Chief Endocrinologist at Crinetics Pharmaceuticals, discusses data on the efficacy and safety of paltusotine for the treatment of acromegaly. Impact of Approval of Pegcetacoplan for Rare Kidney Diseases https://checkrare.com/impact-of-approval-of-pegcetacoplan-for-rare-kidney-diseases/ Carla Nester, MD, University of Iowa Stead Family Children’s Hospital and lead investigator of the VALIANT study, discusses the impact of the recent approval of pegcetacoplan (Empaveli) for patients with C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). Clinical Experience With Iptacopan for Treatment of PNH https://checkrare.com/clinical-experience-with-iptacopan-for-treatment-of-pnh/ Jamie Koprivnikar, MD, Hematologist Oncologist at Hackensack University Medical Center, discusses her clinical experience with iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Linvoseltamab in the Treatment of Relapsed/Refractory Multiple Myeloma https://checkrare.com/linvoseltamab-in-the-treatment-of-relapsed-refractory-multiple-myeloma/ Joshua Richter, MD, Associate Professor of Medicine at the Tisch Cancer Institute, Director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai, discusses the recent U.S. Food and Drug Administration (FDA) approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma (MM). Evaluating Fenfluramine in Patients With Lennox-Gastaut Syndrome https://checkrare.com/evaluating-fenfluramine-in-patients-with-lennox-gastaut-syndrome/ Amelie Lothe, PhD, Global Medical Community Head for Rare Epilepsies at UCB, discusses recent data evaluating fenfluramine in patients with Lennox-Gastaut syndrome. Outpatient Administration of Naxitamab in Patients With Neuroblastoma https://checkrare.com/outpatient-administration-of-naxitamab-in-patients-with-neuroblastoma/ Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses outpatient administration of naxitamab in patients with neuroblastoma.